丙型肝炎药物筛选体系建立与初步应用
|
摘要
丙型肝炎病毒(Hepatitis C virus,HCV)属于黄病毒科,肝炎病毒属,有包膜单股正链RNA病毒,基因组全长约9.6 kb。据估计,全世界约有1.7亿人感染HCV,感染人数不断增加,危害日益严重。HCV—经感染,约80%的病例会建立慢性感染,其中20%慢性感染者最终会发展成为肝硬化、肝癌。目前对丙型肝炎的治疗,主要采用聚乙二醇化干扰素(Peg-IFN)和利巴韦林(Ribavirin,RBV)联合疗法,但至少有约50%患者不能产生持续病毒学应答(SVR),1型HCV感染患者SVR率更低。同时,联合疗法还存在服用吸收率低、毒副作用大和成本偏高等缺点,因此迫切需要建立更为完善的药物筛选方法,筛选新的抗HCV药物。
本研究在引进了2a型嵌合病毒(J6/JFH1)、Huh 7.5.1细胞HCV细胞培养体系(HCV cell culture,HCVcc)的基础上,经细胞培养条件优化和细胞成活率检测,确定了Huh7.5.1细胞的生长曲线。9×104cells/ml接种细胞密度情况下,经过潜伏期后,细胞2-6天进入大量增长的指数生长期,第3天细胞生长至可用作药物筛选的最佳密度。经过对不同感染复数的病毒在细胞中的增殖特性分析,发现病毒株感染细胞后3-7天,为生长的指数增长期,第3天病毒载量为6.5×106IU/ml,为病毒载量检测的最佳时间；病毒株对细胞的最适感染复数为1。在建立了检测药物细胞毒性MTT方法,和荧光定量PCR病毒载量检测方法的基础上,以干扰素α-1b(IFNα-1b)和利巴韦林(RBV)为阳性对照,建立了抗HCV药物筛选体系。结果显示：IFNα-1b无实际细胞毒性,半数有效浓度(EC50)值为1.452IU/ml;利巴韦林半数细胞抑制生长浓度(ICso)值为20.14μg/ml,半数有效浓度(ECso)值为2.553μg/ml,选择指数(SI)值为7.889。分别对IFNα-1b和RBV不同给药方式,不同时间的抗病毒效果检测,发现IFNa-1b预处理细胞18h后加入病毒,RBV在病毒同时感染同时加入,可达到最佳抗病毒效果,二者联合用药的抗病毒效果明显高于单独使用。
用已建立的抗HCV药物筛选方法,初步对15种化合物进行抗病毒效果评价,发现其中6种化合物对HCV RNA的复制有明显抑制活性,分别为：shm-7(IC50,1.089μg/ml；EC50,0.025μg/ml；SI,44).LDX22(IC50,5.752μg/ml；EC50,0.180μg/ml；SI,32).LDX28a(IC50,20.390μg/ml；EC50,0.672μg/ml；SI,30).ZDH7(IC50, 32.640μg/ml；EC50,0.561μg/ml；SI,58).ZDH22(IC50,5.089μg/ml；EC50,0.260μg/ml；SI,20)、ZDH26(IC5o,14.870μg/ml；EC50,0.127μg/ml；SI,116)。其中LDX28a和ZDH7,无明显细胞毒性。其它9种药物(shm-4、shm-9a、shm-14、LDX24、ZCS3、ZCS4、ZCS11、ZCS17、ZDH17)的选择指数明显低于对照药物(RBV)。
综上所述,本研究在建立的HCV细胞培养体系的基础上,以目前标准治疗药物干扰素和利巴韦林为阳性对照,建立了抗HCV药物筛选方法,初步应用于抗HCV药物筛选,从15种备选药物中发现了6种化合物具有一定的抗病毒活性。所建立的方法可以准确、快速的进行抗HCV药物的筛选,为充分利用云南特有药物资源开发抗病毒药物搭建了必要的技术平台。
Hepatitis C virus (HCV), a small and enveloped RNA virus, was classified to Hepacivirus genus of Flaviviridae family. Its genome was a single- stranded positive-sense RNA of 9.6 kb length. It was estimated that 170 million people was infected with HCV worldwide. The increasing of infection case indicated the more severe prevalence. Once the occurrence of HCV infection, about 80% infected individuals will progressed to chronic disease. Among them, about 20% ended with liver failure and hepatocellular carcinoma. The current standard therapy was pegylated interferon-αand ribavirin combined treatment. However, less than 50% patients was shown with a sustained viral response (SVR), the effection of treatment is much poor in patients with HCV lb strains infection. In addition, the low effection rate, the obvious side effects and high cost had hampered its clinical application. It was urgent to develop the new treatment using the more convincing anti-HCV drug screening system.
The successfully established 2a chimeric strains (J6/JFH1) HCV cell culture (Huh 7.5.1) system (HCVcc) had been introduced into our lab. With optimization of cell culture condition and analyze on Huh 7.5.1 cell growth curve, it was found that the cell grown exponentially between 2-6 culture days with started cell density of 9×104 cells/ml. And, the cultured No.3 day could be taken as the test time of cell toxicity. With the different infection multiplicity of infection and followd virus proliferation assay, the exponential growth phase was from 2 to 6 day after virus inoculation. The best determine time was No. 3 day with viral load of 6.5×106 IU/ml. The optimal multiplicity of infection of HCV strains was 1. Furthermore, IFNa-lb and Ribavirin was used as positive control to established MTT cytotoxic assay and real-time PCR viral load quantitaion method to evaluate the antiviral effect of drugs. It was shown that IFNa-lb have no obvious cell toxicity, which half effective concentration value was 1.452 IU/ml. For Ribavirin, half of the cell growth inhibition concentration (IC50) value was determined as 20.14μg/ml, whose half effective concentration (EC50) values was 2.553μg/ml, the calculated selective index (SI) value was 7.889. In parallel, IFNa-lb was shown no obvious cyto-toxicity with EC50 of 1.452 IU/ml. The different drug delivery time and patterns were performed furtherly, the 18 hours after virus inoculation and concurrent of inoculation was shown as the best start interrupte time for IFNa-lb and RBV respectively. The inhibite effect of combinate treatment was better than single using of IFNa-lb or Ribavirin.
With the established screening system, the anti-HCV effects of 15 candidates were tested. Among them, the obvious inhibition effects of 6 compounds were proved. It was listed as shm-7 (IC50:1.089μg/ml, EC50:0.025μg/ml, SI,44), LDX22 (IC50:5.752μg/ml, EC50:0.180μg/ml, SI:32), LDX28a (IC50:20.390μg/ml, EC50:0.672μg/ml, SI:30), ZDH7(IC50:32.640μg/ml, EC50:0.561μg/ml, SI:58), ZDH22 (IC50:5.089μg/ml, EC50: 0.260μg/ml, SI:20) and ZDH26 (IC50:14.870μg/ml, EC50:0.127μg/ml, SI:116). LDX28a and ZDH7 hadn't any cytotoxity. It was notable that selective index of ZDH26 was up to 116, which was much higher than positive control RBV. The anti-HCV effects of remained 9 compounds (shm-4, shm-9a, shm-14, LDX24, ZCS3, ZCS4, ZCS11, ZCS17 and ZDH17) haven't shown here.
In summary, based on the introduced HCV cell culture system, the anti-HCV drug screening system had been established with interferon and ribavirin as a positive control. Using this menthod, the anti-HCV effects of 6 compounds from 15 candidates was determined. This screening system will be taken as a useful tool to discover anti-HCV compound from the prolific drug resource of Yunnan. The promotion of this technique platform on drug industry could be expected.
本研究在引进了2a型嵌合病毒(J6/JFH1)、Huh 7.5.1细胞HCV细胞培养体系(HCV cell culture,HCVcc)的基础上,经细胞培养条件优化和细胞成活率检测,确定了Huh7.5.1细胞的生长曲线。9×104cells/ml接种细胞密度情况下,经过潜伏期后,细胞2-6天进入大量增长的指数生长期,第3天细胞生长至可用作药物筛选的最佳密度。经过对不同感染复数的病毒在细胞中的增殖特性分析,发现病毒株感染细胞后3-7天,为生长的指数增长期,第3天病毒载量为6.5×106IU/ml,为病毒载量检测的最佳时间；病毒株对细胞的最适感染复数为1。在建立了检测药物细胞毒性MTT方法,和荧光定量PCR病毒载量检测方法的基础上,以干扰素α-1b(IFNα-1b)和利巴韦林(RBV)为阳性对照,建立了抗HCV药物筛选体系。结果显示：IFNα-1b无实际细胞毒性,半数有效浓度(EC50)值为1.452IU/ml;利巴韦林半数细胞抑制生长浓度(ICso)值为20.14μg/ml,半数有效浓度(ECso)值为2.553μg/ml,选择指数(SI)值为7.889。分别对IFNα-1b和RBV不同给药方式,不同时间的抗病毒效果检测,发现IFNa-1b预处理细胞18h后加入病毒,RBV在病毒同时感染同时加入,可达到最佳抗病毒效果,二者联合用药的抗病毒效果明显高于单独使用。
用已建立的抗HCV药物筛选方法,初步对15种化合物进行抗病毒效果评价,发现其中6种化合物对HCV RNA的复制有明显抑制活性,分别为：shm-7(IC50,1.089μg/ml；EC50,0.025μg/ml；SI,44).LDX22(IC50,5.752μg/ml；EC50,0.180μg/ml；SI,32).LDX28a(IC50,20.390μg/ml；EC50,0.672μg/ml；SI,30).ZDH7(IC50, 32.640μg/ml；EC50,0.561μg/ml；SI,58).ZDH22(IC50,5.089μg/ml；EC50,0.260μg/ml；SI,20)、ZDH26(IC5o,14.870μg/ml；EC50,0.127μg/ml；SI,116)。其中LDX28a和ZDH7,无明显细胞毒性。其它9种药物(shm-4、shm-9a、shm-14、LDX24、ZCS3、ZCS4、ZCS11、ZCS17、ZDH17)的选择指数明显低于对照药物(RBV)。
综上所述,本研究在建立的HCV细胞培养体系的基础上,以目前标准治疗药物干扰素和利巴韦林为阳性对照,建立了抗HCV药物筛选方法,初步应用于抗HCV药物筛选,从15种备选药物中发现了6种化合物具有一定的抗病毒活性。所建立的方法可以准确、快速的进行抗HCV药物的筛选,为充分利用云南特有药物资源开发抗病毒药物搭建了必要的技术平台。
Hepatitis C virus (HCV), a small and enveloped RNA virus, was classified to Hepacivirus genus of Flaviviridae family. Its genome was a single- stranded positive-sense RNA of 9.6 kb length. It was estimated that 170 million people was infected with HCV worldwide. The increasing of infection case indicated the more severe prevalence. Once the occurrence of HCV infection, about 80% infected individuals will progressed to chronic disease. Among them, about 20% ended with liver failure and hepatocellular carcinoma. The current standard therapy was pegylated interferon-αand ribavirin combined treatment. However, less than 50% patients was shown with a sustained viral response (SVR), the effection of treatment is much poor in patients with HCV lb strains infection. In addition, the low effection rate, the obvious side effects and high cost had hampered its clinical application. It was urgent to develop the new treatment using the more convincing anti-HCV drug screening system.
The successfully established 2a chimeric strains (J6/JFH1) HCV cell culture (Huh 7.5.1) system (HCVcc) had been introduced into our lab. With optimization of cell culture condition and analyze on Huh 7.5.1 cell growth curve, it was found that the cell grown exponentially between 2-6 culture days with started cell density of 9×104 cells/ml. And, the cultured No.3 day could be taken as the test time of cell toxicity. With the different infection multiplicity of infection and followd virus proliferation assay, the exponential growth phase was from 2 to 6 day after virus inoculation. The best determine time was No. 3 day with viral load of 6.5×106 IU/ml. The optimal multiplicity of infection of HCV strains was 1. Furthermore, IFNa-lb and Ribavirin was used as positive control to established MTT cytotoxic assay and real-time PCR viral load quantitaion method to evaluate the antiviral effect of drugs. It was shown that IFNa-lb have no obvious cell toxicity, which half effective concentration value was 1.452 IU/ml. For Ribavirin, half of the cell growth inhibition concentration (IC50) value was determined as 20.14μg/ml, whose half effective concentration (EC50) values was 2.553μg/ml, the calculated selective index (SI) value was 7.889. In parallel, IFNa-lb was shown no obvious cyto-toxicity with EC50 of 1.452 IU/ml. The different drug delivery time and patterns were performed furtherly, the 18 hours after virus inoculation and concurrent of inoculation was shown as the best start interrupte time for IFNa-lb and RBV respectively. The inhibite effect of combinate treatment was better than single using of IFNa-lb or Ribavirin.
With the established screening system, the anti-HCV effects of 15 candidates were tested. Among them, the obvious inhibition effects of 6 compounds were proved. It was listed as shm-7 (IC50:1.089μg/ml, EC50:0.025μg/ml, SI,44), LDX22 (IC50:5.752μg/ml, EC50:0.180μg/ml, SI:32), LDX28a (IC50:20.390μg/ml, EC50:0.672μg/ml, SI:30), ZDH7(IC50:32.640μg/ml, EC50:0.561μg/ml, SI:58), ZDH22 (IC50:5.089μg/ml, EC50: 0.260μg/ml, SI:20) and ZDH26 (IC50:14.870μg/ml, EC50:0.127μg/ml, SI:116). LDX28a and ZDH7 hadn't any cytotoxity. It was notable that selective index of ZDH26 was up to 116, which was much higher than positive control RBV. The anti-HCV effects of remained 9 compounds (shm-4, shm-9a, shm-14, LDX24, ZCS3, ZCS4, ZCS11, ZCS17 and ZDH17) haven't shown here.
In summary, based on the introduced HCV cell culture system, the anti-HCV drug screening system had been established with interferon and ribavirin as a positive control. Using this menthod, the anti-HCV effects of 6 compounds from 15 candidates was determined. This screening system will be taken as a useful tool to discover anti-HCV compound from the prolific drug resource of Yunnan. The promotion of this technique platform on drug industry could be expected.
引文
[1]Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease[J]. Hepatology, 1991,14:381-388.
[2]Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses:proposals for standardization. International Committee on Virus Taxonomy[J]. Arch Virol,1998,12: 2493-2503.
[3]Choo Q, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[J]. Science,1989,244:359-362.
[4]Harada S, Watanabe Y, Takeuchi K, et al. Expression of processed core protein of hepatitis C virus in mammalian cells[J]. J Virol,1991,65:3015-3021.
[5]Liu Q, Tackney C, Bhat RA, et al. Regulated processing of hepatitis C virus core protein is linked to sub lularlocalization[J]. J Virol,1997,71:657-662.
[6]Suzuki R, Tamura K, Li J, et al. Ubiquitin-mediated degradation of hepatitis C virus core protein is regulated by processing at its carboxyl terminus[J]. Virology,2001,280: 301-309.
[7]Yasui K, Wakita T, Tsukiyama-Kohara K, et al. The native form and maturation process of hepatitis C virus core protein[J]. J Virol,1998,72:6048-6055.
[8]Suzuki T, Suzuki R. Maturation and assembly of hepatitis C virus core protein. In:M. Kalitzky, P. Borowski (Eds.), Molecular Biology of the Flavivirus, Horizon Bioscience, Norfolk, UK,2006, pp:295-311.
[9]Sakai A, Claire MS, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences[J]. Proc Natl Acad Sci, USA,2003,100:11646-11651.
[10]Grakoui A, McCourt DW, Wychowski C, et al. A second hepatitis C virus-encoded proteinase[J]. Proc Natl Acad Sci, USA,1993,90:10583-10587.
[11]Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science,1999,285:110-113.
[12]Khromykh A, Westaway EG. Subgenomic replicons of the flavivirus Kunjin: construction and applications[J]. J Virol,1997,71:1497-1505.
[13]Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras [J]. Proc Natl Acad Sci,2006,103:7408-7413.
[14]Kolykhalov A, Mihalik K, Feinstone SM, et al. Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3'nontranslated region are essential for virus replication in vivo[J]. J Virol,2000,74:2046-2051.
[15]Wolk B, Sansonno D, Krausslich HG, et al. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines[J]. J Virol,2000,74:2293-2304.
[16]Kwong D, Kim JL, Lin C, Structure and function of hepatitis C virus NS3 helicase[J]. Curr Top Microbiol Immunol,2000,242:171-196.
[17]Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-clraving protease activity [J]. J Biomol Screening,2002,7:149
[18]Frick DN, Rypma RS, Lam AM, et al. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently [J]. J Biol Chem, 2004,279:1269-1280.
[19]Y ao N, Reichert P, Taremi S, et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase[J]. Structure,1999,7:1353-1363
[20]Gao L, Aizaki H, He JW, et al. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft[J]. J Virol,2004,78:3480-3488.
[21]Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations[J]. J Virol,2001,75:4614-4624.
[22]McHutchison JG, Shiffman ML, Gordon SC, et al. Sustained virologic response (SVR) to interferon-alpha-2b±ribavirin therapy at 6 months reliably predicts long-term clearance of HCVat 5-year follow-up[J]. J Hepatol,2006,44:275-77.
[23]Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virological response after treatment with peginterferon alfa-2a (Pegasys) alone or in combination with ribavirin (Copegus):5-year follow-up and the criteria for a cure[J]. J Hepatol,2007,46:S3.
[24]Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon[J]. J Med,1986,315:1575-1578.
[25]Lau DT, Kleiner DE, Ghany MG, et al.10-year follow-up after interferon-alpha therapy for chronic hepatitis C[J]. Hepatology,1998,28:1121-1127.
[26]Butcher SJ, Grimes JM, Makeyev EV, et al. A mechanism for initiating RNA-dependent RNA polymerization[J]. Nature,2001,410:235-240.
[27]Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81[J]. Science,1998,282:938-941.
[28]Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J]. Nature,2007,446:801-805.
[29]Griffin SD,Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug[J]. Amantadine FEBSLett,2003,535: 34-38
[30]Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis- clraving protease activity [J]. J Biomol Screening,2002,7:149
[31]Myles DC. Recent advances in the discovery of small molecule therapies for HCV[J]. Curr Opin Drug Discov Devel,2001,4:411
[32]Foy E, Li K, Wang C, et al. Regulation ofinterferon regulatory factor-3 by the hepatitid C virus serine protease[J]. Science,2003,300:1145-48
[33]Stephane C, Jean-Michel P, Interferon-based therapy of hepatitis C[J]. Advanced Drug Delivery Reviews,2007,59:1222-41
[34]Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C[J]. Hepatology,2001,34:395-403.
[35]Wu JZ, Larson G, Walker H, et al. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase Ⅱ:implications for ribavirin metabolism in erythrocytes[J]. Antimicrob Agents Chemother,2005,49:2164-2171.
[36]Maag D, Castro C, Hong Z, et al. Hepatitis C virus RNAdependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin[J]. J Biol Chem,2001,276: 46094-46098.
[37]Vo NV, Young KC, Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase [J]. Biochemistry,2003,42:10462-10471.
[38]Markland W, McQuaid TJ, Jain J, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497:a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon[J]. Antimicrob Agents Chemother,2000,44: 859-866.
[39]Reichard O, Andersson J, Schvarcz R, et al. Ribavirin treatment or chronic hepatitis C[J]. Lancet,1991,337:1058-1061.
[40]Bisceglie AM, Shindo M, Fong TL, et al. A pilot tudy of ribavirin therapy for chronic hepatitis C[J]. Hepatology,1992,16:649-654.
[41]Dusheiko G, Main J, Thomas H, et al. Rbavirin treatment for patients with chronic hepatitis C:results of a lacebo-controlled study [J]. J Hepatol,1996,25:591-598.
[42]Reichard O, Yun ZB, Sonnerborg A, et al. Hepatitis C viral NA titers in serum prior to, during, and after oral treatment with rbavirin for chronic hepatitis C[J]. J Med,1993,41: 99-102.
[43]Brillanti S, Garson J, Foli M, et al. Apilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C[J]. Gastroenterology, 1994,107:812-817.
[44]Balan V, Nelson DR, Sulkowski MS, et al. A Phase Ⅰ/Ⅱ study evaluating escalating doses of recombinant human albumin-interferonalpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy[J]. Antivir Ther, 2006,11:35-45.
[45]Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys[J]. J Pharmacol,2002,303:540-548.
[46]Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients[J]. J Hepatol,2006,44: 671-678.
[47]Zeuzem S, Benhamou Y, Bain V, et al. Antiviral response at week 12 following completion of treatment with albinterferon alpha-2b plus ribavirin in genotype 1, interferon-naive, chronic hepatitis patients[J]. J Hepatol,2007,46:293-95.
[48]Bain VG, Marotta P, Kaita K, et al. Comparable antiviral response rates with albumin interferon alpha-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C[J]. J Hepatol,2007,46:S7.
[49]Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling[J].Nat Biotechnol,1999,17:793-797.
[50]Keeffe EB, Hollinger FB, Therapy of hepatitis C:consensus interferon trials[J]. J Hepatol,1997,26:101-107.
[51]Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon[J]. J Interferon Cytokine Res,1996,16:489-499.
[52]Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-Conl with natural recombinant interferons-alpha:antiviral, antiproliferative, and natural killer-inducing activities[J]. J Interf Res,1992,12:55-59.
[53]Miglioresi L, Bacosi M, Russo F, et al. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection[J]. Hepatol Res,2003,27: 253-259.
[54]Bocher WO, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy [J]. Liver Int,2006,26:319-325.
[55]Sjogren MH, Sjogren JR, Lyons MF,et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin[J]. Dig Dis Sci,2007,52:1540-1547.
[56]Tam R, Lim C, Bard J, et al. Immunomodulatory activities of viramidine, a liver- targeting ribavirin prodrug, in vitro and in vivo. In:Abstracts of the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, AASLD, Alexandria, VA, USA.2001,715:351
[57]Markland W, McQuaid TJ, Jain J, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497:a comparison with ribavirin and demonstration of antiviral additivity with a interferon[J]. Antimicrob Agents Chemother,2000,44: 859-66.
[58]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426:186-199
[59]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426:186-189.
[60]Hinrichsen H, Benhamou Y, Wedemeyer H,et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients[J]. Gastroenterology,2004,127:1347-1355.
[61]Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 [J]. J Virol,2004,78: 7352-7359.
[62]Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C[J]. Hepatology,2005,41:832-835.
[63]Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061:structural analysis indicates different resistance mechanisms[J]. J Biol Chem,2004,279:17508-17514.
[64]Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease[J]. Antimivrob Agents Chemother,2006,50:899-909
[65]Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells[J]. Antimicrob Agents Chemother,2006,50:1813-1822.
[66]Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1b, multiple- dose study of VX-950, a hepatitis C virus protease inhibitor. In:Proceedings of the 56th Annual Meeting of the American Association for the Study of LiverDiseases, San Francisco, CA, Absst.,96
[67]Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of 1R,5S)-N-[3-amino-l-(cyclobutylmethyl)-2,3-dioxopropyl]-[2(S)-[[[(1,1-dimethylethyl)amino] carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:a potential therapeutic agent for the treatment of hepatitis C infection[J]. J Med Chem,2006,49:6074-6086.
[68]Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034[J]. Antiviral Res,2006,70: 28-38.
[69]Migliaccio D, Biseck E, Hugle, et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA, dependent RNA polymerase[J]. J Biol Chem, 2002,277:593-601
[70]Klumpp K, Leveque V, Le Pogam, et al.The novel nucleoside analog R1479 is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture[J]. J Hepatol,2008,48:319-322
[71]Leveque V, Le Pogam S, Kang H, et al. Antiviral potency of R-1479, active compound derived in vivo from prodrug R-1626, demonstrated across HCV genotypes 1-6 in NS5B recombinant enzymes and HCV replicons[J]. J Hepatol,2008,48:319.
[72]Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin[J]. Hepatology,2008,48(2):385-397.
[73]Pockros P, Nelson D, Godofsky E, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy[J]. Hepatology,2008,48:1349-1350.
[74]Chandra P, Raible D, Moyer L, et al. Safety and pharmacokinetics of the non-nucloside polymerase inhibitor, HCV-796:results of a randomized,double-blind placebo controlled, ascending single-dose study in healthy subjects[J]. Hepatol,2006, 44:S208.
[75]Crabbe R, Vuagniaux G, Dumont JM, et al. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C[J]. Expert Opin Investig Drugs,2009,18:211-220.
[76]Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus[J]. Hepatology,2008,47(3):817-826.
[77]Flisiak R, Feinman SV, Jablkowski M, et al. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients.43rd EASL Conference.Italy, Milan Italy, 2008.
[78]Wohlfarth C, Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C[J]. Acta Pharmacol Sin,2009,30(1):25-30.
[79]Mathy JE, Ma S, Compton T, et al. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance[J]. Antimicrob Agents Chemother,2008,52(9):3267-3275.
[80]Maccjak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus- RNA-dependent translation and replication of a chimeric HCV poliovirus rsing synthetic atabilized ribozymes[J]. J hepatology,2000,120:85
[81]Mc Hutchison JG, Patel K, Pockros P, et al. Aphase 1 trial of all antisense inhibitor of hepatitis C virus(ISIS 14803), administered to chronic hepatitis C patients[J]. J Hepatol, 2006,44:88-96
[82]Arvind S, Samuel K. Plant-derived compounds in clinical trials[J]. Drug Discovery Today,2008,13:56-64
[83]Jeffrey MJ, Lawrence F. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection[J]. J antimicrob Agent Hemother,2001:517
[84]Frese M, Pietschmann T, Moradpour D,et al. Interferon- alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway[J]. J Gen,2001, 82(4):723-33
[85]Paul Z, Edward M, Murray E, et al. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication[J]. Anal Biochem,2004, 334(2):344-355
[86]Ikeda M,.Abe K, Dansako H, et al. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system[J]. Biochem Biophys Res Commun,2005,329(4):1350-9.
[87]Masanori I, Kyoko M, Yasuo A, et al. Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-a[J]. FEBS Letters,2009,583(9): 1434-8
[88]Paul Z, Edward M, Murray E, et al. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication[J]. Anal Biochem,2004, 334(2):344-355
[89]Nigel B, Richard BP. Sreening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system[J]. Antiviral Res,2005,67(2): 76-82
[90]Mike W, Jeffrey H, Paul. L, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity[J]. J Biomol Screen,2002, 7(2):149-54
[91]Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCVreplicon cells [J]. Antimicrob Agents Chemother,2006,50(5):1813-22
[92]Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees [J]. J Hepatology, 2004,39(6):1709-20
[93]Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles[J]. J Virol,1998,72(4):2589-99
[94]Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization[J]. Proc Natl Acad Sci, 1994,91(16):7792-6
[95]Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus[J]. Proc Natl Acad Sci USA,1994,91(4):1294-8
[96]Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers[J]. Nat Med,2001,7(8):927-33
[97]Vanwolleghem T, Bukh J, Meuleman P, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain[J]. Hepatology,2008,47(6):1846-55
[98]De R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C[J]. Nature,2005,436:953-960.
[99]Grakoui A, McCourt DW, Wychowski C, et al. Characterization of the hepatitis C virus-encoded serine proteinase:determination of proteinase-dependent polyprotein clravage sites[J]. J Virol,1993,67:2832-43
[99]Tomei L, Failla C, Santolini E, et al. NS3 is a serine protease required for processing of hepatitis C virus polyprotein[J]. J Virol,1993,67:4017-4026
[100]Patel K, Pockros P. Aphase 1 t rial ofall antisense inhibitor of hepatitis C virus (ISIS 14803),adminis2 tered to chronic hepatitis C patients[J]. J Hepatol,2006,44:88296.
[101]Fire A, Xu S, Montgomery MK, et al. Potent and specific genet2 ic interference by double2st randed RNA in Caenorhabditis ele2 gans[J]. Nature,1998,391:8062811.
[102]Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science,1999,285:110-113.
[103]Pietschmann T, Lohmann V, Rutter G, et al. Characterization of cell lines carrying selfreplicating hepatitis C virus RNAs[J]. J Virol,2001,75(3):1252-1264.
[104]Lagging LM, Meyer K, Owens RJ, et al. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus[J]. J Virol,1998,72(5):3539-46
[105]Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus(HCV) trimera mouse:a model for evaluation of agents against HCV[J]. J Infect Dis,2002,185(2):153-61
[106]Owsianka A, Tar AW, Juttla VS, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein[J]. J Virol,2005, 79(17):11095-104
[107]Lindenbach BD, Evans MMJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture[J]. Science,2005,309(5734):623-6
[108]Akazawa D, Morikawa K, Murayama A, et al. CD81 expression is impornant for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection[J]. J Virol,2007,81(10):5036-45'
[109]Wang C, Gale M, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication[J]. Mol Cell,2005,18(4): 425-34
[110]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426(6963):186-9
[112]Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-Cmethylcytidine[J]. J Med Chem,2006,49(22); 6614-20
[113]Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs[J]. Proc Natl Acad Sci,2003,100(1): 235-40
[114]Kapadia SB, Brideau A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs[J]. Proc Natl Acad Sci,2003,100(4):2014-18
[115]Michaela I, Jeroen W, Allan GN. Angus,et al. A reporter cell line for rapid and sensitive evaluation of hepatitis C virusinfectivity and replication[J]. J Antiviral Res, 2009,83(2):148-55
[116]Kneteman NM, Weiner AJ, O'Connell J, et al. Anti-HCV therapies in chimeric SCID-Alb/uPA mice parallel outcomes in human clinical application[J]. Hepatology, 2006,43(6):1346-53
[117]Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients[J]. Gastroenterology.2004,127(5):1347-55.
[118]Philip M, Geert L. The human liver-Upa-SCID mouse:A model for the evaluation of antiviral compounds against HBV and HCV[J]. Antiviral Res,2008,80(3); 231-8
[119]Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J]. Mol Cell,2005,19(1):111-22
[2]Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses:proposals for standardization. International Committee on Virus Taxonomy[J]. Arch Virol,1998,12: 2493-2503.
[3]Choo Q, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[J]. Science,1989,244:359-362.
[4]Harada S, Watanabe Y, Takeuchi K, et al. Expression of processed core protein of hepatitis C virus in mammalian cells[J]. J Virol,1991,65:3015-3021.
[5]Liu Q, Tackney C, Bhat RA, et al. Regulated processing of hepatitis C virus core protein is linked to sub lularlocalization[J]. J Virol,1997,71:657-662.
[6]Suzuki R, Tamura K, Li J, et al. Ubiquitin-mediated degradation of hepatitis C virus core protein is regulated by processing at its carboxyl terminus[J]. Virology,2001,280: 301-309.
[7]Yasui K, Wakita T, Tsukiyama-Kohara K, et al. The native form and maturation process of hepatitis C virus core protein[J]. J Virol,1998,72:6048-6055.
[8]Suzuki T, Suzuki R. Maturation and assembly of hepatitis C virus core protein. In:M. Kalitzky, P. Borowski (Eds.), Molecular Biology of the Flavivirus, Horizon Bioscience, Norfolk, UK,2006, pp:295-311.
[9]Sakai A, Claire MS, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences[J]. Proc Natl Acad Sci, USA,2003,100:11646-11651.
[10]Grakoui A, McCourt DW, Wychowski C, et al. A second hepatitis C virus-encoded proteinase[J]. Proc Natl Acad Sci, USA,1993,90:10583-10587.
[11]Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science,1999,285:110-113.
[12]Khromykh A, Westaway EG. Subgenomic replicons of the flavivirus Kunjin: construction and applications[J]. J Virol,1997,71:1497-1505.
[13]Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras [J]. Proc Natl Acad Sci,2006,103:7408-7413.
[14]Kolykhalov A, Mihalik K, Feinstone SM, et al. Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3'nontranslated region are essential for virus replication in vivo[J]. J Virol,2000,74:2046-2051.
[15]Wolk B, Sansonno D, Krausslich HG, et al. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines[J]. J Virol,2000,74:2293-2304.
[16]Kwong D, Kim JL, Lin C, Structure and function of hepatitis C virus NS3 helicase[J]. Curr Top Microbiol Immunol,2000,242:171-196.
[17]Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-clraving protease activity [J]. J Biomol Screening,2002,7:149
[18]Frick DN, Rypma RS, Lam AM, et al. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently [J]. J Biol Chem, 2004,279:1269-1280.
[19]Y ao N, Reichert P, Taremi S, et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase[J]. Structure,1999,7:1353-1363
[20]Gao L, Aizaki H, He JW, et al. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft[J]. J Virol,2004,78:3480-3488.
[21]Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations[J]. J Virol,2001,75:4614-4624.
[22]McHutchison JG, Shiffman ML, Gordon SC, et al. Sustained virologic response (SVR) to interferon-alpha-2b±ribavirin therapy at 6 months reliably predicts long-term clearance of HCVat 5-year follow-up[J]. J Hepatol,2006,44:275-77.
[23]Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virological response after treatment with peginterferon alfa-2a (Pegasys) alone or in combination with ribavirin (Copegus):5-year follow-up and the criteria for a cure[J]. J Hepatol,2007,46:S3.
[24]Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon[J]. J Med,1986,315:1575-1578.
[25]Lau DT, Kleiner DE, Ghany MG, et al.10-year follow-up after interferon-alpha therapy for chronic hepatitis C[J]. Hepatology,1998,28:1121-1127.
[26]Butcher SJ, Grimes JM, Makeyev EV, et al. A mechanism for initiating RNA-dependent RNA polymerization[J]. Nature,2001,410:235-240.
[27]Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81[J]. Science,1998,282:938-941.
[28]Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J]. Nature,2007,446:801-805.
[29]Griffin SD,Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug[J]. Amantadine FEBSLett,2003,535: 34-38
[30]Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis- clraving protease activity [J]. J Biomol Screening,2002,7:149
[31]Myles DC. Recent advances in the discovery of small molecule therapies for HCV[J]. Curr Opin Drug Discov Devel,2001,4:411
[32]Foy E, Li K, Wang C, et al. Regulation ofinterferon regulatory factor-3 by the hepatitid C virus serine protease[J]. Science,2003,300:1145-48
[33]Stephane C, Jean-Michel P, Interferon-based therapy of hepatitis C[J]. Advanced Drug Delivery Reviews,2007,59:1222-41
[34]Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C[J]. Hepatology,2001,34:395-403.
[35]Wu JZ, Larson G, Walker H, et al. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase Ⅱ:implications for ribavirin metabolism in erythrocytes[J]. Antimicrob Agents Chemother,2005,49:2164-2171.
[36]Maag D, Castro C, Hong Z, et al. Hepatitis C virus RNAdependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin[J]. J Biol Chem,2001,276: 46094-46098.
[37]Vo NV, Young KC, Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase [J]. Biochemistry,2003,42:10462-10471.
[38]Markland W, McQuaid TJ, Jain J, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497:a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon[J]. Antimicrob Agents Chemother,2000,44: 859-866.
[39]Reichard O, Andersson J, Schvarcz R, et al. Ribavirin treatment or chronic hepatitis C[J]. Lancet,1991,337:1058-1061.
[40]Bisceglie AM, Shindo M, Fong TL, et al. A pilot tudy of ribavirin therapy for chronic hepatitis C[J]. Hepatology,1992,16:649-654.
[41]Dusheiko G, Main J, Thomas H, et al. Rbavirin treatment for patients with chronic hepatitis C:results of a lacebo-controlled study [J]. J Hepatol,1996,25:591-598.
[42]Reichard O, Yun ZB, Sonnerborg A, et al. Hepatitis C viral NA titers in serum prior to, during, and after oral treatment with rbavirin for chronic hepatitis C[J]. J Med,1993,41: 99-102.
[43]Brillanti S, Garson J, Foli M, et al. Apilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C[J]. Gastroenterology, 1994,107:812-817.
[44]Balan V, Nelson DR, Sulkowski MS, et al. A Phase Ⅰ/Ⅱ study evaluating escalating doses of recombinant human albumin-interferonalpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy[J]. Antivir Ther, 2006,11:35-45.
[45]Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys[J]. J Pharmacol,2002,303:540-548.
[46]Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients[J]. J Hepatol,2006,44: 671-678.
[47]Zeuzem S, Benhamou Y, Bain V, et al. Antiviral response at week 12 following completion of treatment with albinterferon alpha-2b plus ribavirin in genotype 1, interferon-naive, chronic hepatitis patients[J]. J Hepatol,2007,46:293-95.
[48]Bain VG, Marotta P, Kaita K, et al. Comparable antiviral response rates with albumin interferon alpha-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C[J]. J Hepatol,2007,46:S7.
[49]Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling[J].Nat Biotechnol,1999,17:793-797.
[50]Keeffe EB, Hollinger FB, Therapy of hepatitis C:consensus interferon trials[J]. J Hepatol,1997,26:101-107.
[51]Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon[J]. J Interferon Cytokine Res,1996,16:489-499.
[52]Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-Conl with natural recombinant interferons-alpha:antiviral, antiproliferative, and natural killer-inducing activities[J]. J Interf Res,1992,12:55-59.
[53]Miglioresi L, Bacosi M, Russo F, et al. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection[J]. Hepatol Res,2003,27: 253-259.
[54]Bocher WO, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy [J]. Liver Int,2006,26:319-325.
[55]Sjogren MH, Sjogren JR, Lyons MF,et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin[J]. Dig Dis Sci,2007,52:1540-1547.
[56]Tam R, Lim C, Bard J, et al. Immunomodulatory activities of viramidine, a liver- targeting ribavirin prodrug, in vitro and in vivo. In:Abstracts of the Fifty-second Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, TX, AASLD, Alexandria, VA, USA.2001,715:351
[57]Markland W, McQuaid TJ, Jain J, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497:a comparison with ribavirin and demonstration of antiviral additivity with a interferon[J]. Antimicrob Agents Chemother,2000,44: 859-66.
[58]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426:186-199
[59]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426:186-189.
[60]Hinrichsen H, Benhamou Y, Wedemeyer H,et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients[J]. Gastroenterology,2004,127:1347-1355.
[61]Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 [J]. J Virol,2004,78: 7352-7359.
[62]Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C[J]. Hepatology,2005,41:832-835.
[63]Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061:structural analysis indicates different resistance mechanisms[J]. J Biol Chem,2004,279:17508-17514.
[64]Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease[J]. Antimivrob Agents Chemother,2006,50:899-909
[65]Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells[J]. Antimicrob Agents Chemother,2006,50:1813-1822.
[66]Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1b, multiple- dose study of VX-950, a hepatitis C virus protease inhibitor. In:Proceedings of the 56th Annual Meeting of the American Association for the Study of LiverDiseases, San Francisco, CA, Absst.,96
[67]Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of 1R,5S)-N-[3-amino-l-(cyclobutylmethyl)-2,3-dioxopropyl]-[2(S)-[[[(1,1-dimethylethyl)amino] carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:a potential therapeutic agent for the treatment of hepatitis C infection[J]. J Med Chem,2006,49:6074-6086.
[68]Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034[J]. Antiviral Res,2006,70: 28-38.
[69]Migliaccio D, Biseck E, Hugle, et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA, dependent RNA polymerase[J]. J Biol Chem, 2002,277:593-601
[70]Klumpp K, Leveque V, Le Pogam, et al.The novel nucleoside analog R1479 is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture[J]. J Hepatol,2008,48:319-322
[71]Leveque V, Le Pogam S, Kang H, et al. Antiviral potency of R-1479, active compound derived in vivo from prodrug R-1626, demonstrated across HCV genotypes 1-6 in NS5B recombinant enzymes and HCV replicons[J]. J Hepatol,2008,48:319.
[72]Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin[J]. Hepatology,2008,48(2):385-397.
[73]Pockros P, Nelson D, Godofsky E, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy[J]. Hepatology,2008,48:1349-1350.
[74]Chandra P, Raible D, Moyer L, et al. Safety and pharmacokinetics of the non-nucloside polymerase inhibitor, HCV-796:results of a randomized,double-blind placebo controlled, ascending single-dose study in healthy subjects[J]. Hepatol,2006, 44:S208.
[75]Crabbe R, Vuagniaux G, Dumont JM, et al. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C[J]. Expert Opin Investig Drugs,2009,18:211-220.
[76]Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus[J]. Hepatology,2008,47(3):817-826.
[77]Flisiak R, Feinman SV, Jablkowski M, et al. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients.43rd EASL Conference.Italy, Milan Italy, 2008.
[78]Wohlfarth C, Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C[J]. Acta Pharmacol Sin,2009,30(1):25-30.
[79]Mathy JE, Ma S, Compton T, et al. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance[J]. Antimicrob Agents Chemother,2008,52(9):3267-3275.
[80]Maccjak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus- RNA-dependent translation and replication of a chimeric HCV poliovirus rsing synthetic atabilized ribozymes[J]. J hepatology,2000,120:85
[81]Mc Hutchison JG, Patel K, Pockros P, et al. Aphase 1 trial of all antisense inhibitor of hepatitis C virus(ISIS 14803), administered to chronic hepatitis C patients[J]. J Hepatol, 2006,44:88-96
[82]Arvind S, Samuel K. Plant-derived compounds in clinical trials[J]. Drug Discovery Today,2008,13:56-64
[83]Jeffrey MJ, Lawrence F. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection[J]. J antimicrob Agent Hemother,2001:517
[84]Frese M, Pietschmann T, Moradpour D,et al. Interferon- alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway[J]. J Gen,2001, 82(4):723-33
[85]Paul Z, Edward M, Murray E, et al. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication[J]. Anal Biochem,2004, 334(2):344-355
[86]Ikeda M,.Abe K, Dansako H, et al. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system[J]. Biochem Biophys Res Commun,2005,329(4):1350-9.
[87]Masanori I, Kyoko M, Yasuo A, et al. Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-a[J]. FEBS Letters,2009,583(9): 1434-8
[88]Paul Z, Edward M, Murray E, et al. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication[J]. Anal Biochem,2004, 334(2):344-355
[89]Nigel B, Richard BP. Sreening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system[J]. Antiviral Res,2005,67(2): 76-82
[90]Mike W, Jeffrey H, Paul. L, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity[J]. J Biomol Screen,2002, 7(2):149-54
[91]Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCVreplicon cells [J]. Antimicrob Agents Chemother,2006,50(5):1813-22
[92]Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees [J]. J Hepatology, 2004,39(6):1709-20
[93]Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles[J]. J Virol,1998,72(4):2589-99
[94]Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization[J]. Proc Natl Acad Sci, 1994,91(16):7792-6
[95]Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus[J]. Proc Natl Acad Sci USA,1994,91(4):1294-8
[96]Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers[J]. Nat Med,2001,7(8):927-33
[97]Vanwolleghem T, Bukh J, Meuleman P, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain[J]. Hepatology,2008,47(6):1846-55
[98]De R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C[J]. Nature,2005,436:953-960.
[99]Grakoui A, McCourt DW, Wychowski C, et al. Characterization of the hepatitis C virus-encoded serine proteinase:determination of proteinase-dependent polyprotein clravage sites[J]. J Virol,1993,67:2832-43
[99]Tomei L, Failla C, Santolini E, et al. NS3 is a serine protease required for processing of hepatitis C virus polyprotein[J]. J Virol,1993,67:4017-4026
[100]Patel K, Pockros P. Aphase 1 t rial ofall antisense inhibitor of hepatitis C virus (ISIS 14803),adminis2 tered to chronic hepatitis C patients[J]. J Hepatol,2006,44:88296.
[101]Fire A, Xu S, Montgomery MK, et al. Potent and specific genet2 ic interference by double2st randed RNA in Caenorhabditis ele2 gans[J]. Nature,1998,391:8062811.
[102]Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science,1999,285:110-113.
[103]Pietschmann T, Lohmann V, Rutter G, et al. Characterization of cell lines carrying selfreplicating hepatitis C virus RNAs[J]. J Virol,2001,75(3):1252-1264.
[104]Lagging LM, Meyer K, Owens RJ, et al. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus[J]. J Virol,1998,72(5):3539-46
[105]Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus(HCV) trimera mouse:a model for evaluation of agents against HCV[J]. J Infect Dis,2002,185(2):153-61
[106]Owsianka A, Tar AW, Juttla VS, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein[J]. J Virol,2005, 79(17):11095-104
[107]Lindenbach BD, Evans MMJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture[J]. Science,2005,309(5734):623-6
[108]Akazawa D, Morikawa K, Murayama A, et al. CD81 expression is impornant for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection[J]. J Virol,2007,81(10):5036-45'
[109]Wang C, Gale M, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication[J]. Mol Cell,2005,18(4): 425-34
[110]Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature,2003,426(6963):186-9
[112]Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-Cmethylcytidine[J]. J Med Chem,2006,49(22); 6614-20
[113]Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs[J]. Proc Natl Acad Sci,2003,100(1): 235-40
[114]Kapadia SB, Brideau A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs[J]. Proc Natl Acad Sci,2003,100(4):2014-18
[115]Michaela I, Jeroen W, Allan GN. Angus,et al. A reporter cell line for rapid and sensitive evaluation of hepatitis C virusinfectivity and replication[J]. J Antiviral Res, 2009,83(2):148-55
[116]Kneteman NM, Weiner AJ, O'Connell J, et al. Anti-HCV therapies in chimeric SCID-Alb/uPA mice parallel outcomes in human clinical application[J]. Hepatology, 2006,43(6):1346-53
[117]Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients[J]. Gastroenterology.2004,127(5):1347-55.
[118]Philip M, Geert L. The human liver-Upa-SCID mouse:A model for the evaluation of antiviral compounds against HBV and HCV[J]. Antiviral Res,2008,80(3); 231-8
[119]Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J]. Mol Cell,2005,19(1):111-22